024sek
5,2 %
Date:2026-02-16Time:18:00:00Latest report:Q4-2025List:SpotlightTicker:PHAL
Market Cap:15 msekEnterprise Value:18 msekNet Sales:- msekEarnings:-7,11 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,24
MA50:0,29
MA200:0,37
Price/MA200:-34,0 %
RSI (14):43,8
Price/MA50:-17,7 %

Description

PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.

Biotechnology